Online inquiry

IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ3666MR)

This product GTTS-WQ3666MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F11 gene. The antibody can be applied in Thromobosis research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_000128.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	2160
UniProt ID	P03951

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3666MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ3794MR	IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	BAY-86-6150
GTTS-WQ4728MR	IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	BOS161721
GTTS-WQ7565MR	IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	GC33
GTTS-WQ7602MR	IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	G-CSF-Fc-PEG
GTTS-WQ4710MR	IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	BMS-986168
GTTS-WQ12788MR	IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	OMP-59R5
GTTS-WQ15990MR	IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	ZTS-00521505
GTTS-WQ14631MR	IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	SC0001-SCX

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST